Large Market Opportunity Expansion
Updated 2028 TAM for AI and data center optical transceivers expanded from approximately $17B to $47B (≈+176%), driven by projected deployments of 1.6Tb and 3.2Tb transceivers and co-packaged optics. Serviceable addressable market (SAM) increased from ~$1B–$2.5B to ~$2B–$4B (roughly 2x at the low end; ~1.6x at the high end).
Customer Traction and Design-Win Progress
Four major customers (Fortune 500/Global 500) are at Stage 3/prototyping in the design-win pipeline; company expects 1–2 additional Tier 1 customers to reach Stage 3 before the end of Q3 2026. Multiple devices from foundry partners are expected in Q3–Q4 2026.
Commercial Integration with Silicon Photonics Ecosystem
PDK integrations and partnerships with foundry ecosystems (Tower Semiconductor, GlobalFoundries via GDS Factory, SilTerra with Luceda Photonics) and advancement of PDK 1.1 demonstrate stronger compatibility and readiness for semiconductor foundry workflows and potential high-volume manufacturing.
Demonstrated Reliability Progress
Latest-generation electro-optic polymer materials passed key Telcordia-related stress testing and accelerated environmental tests (including 85°C/85% humidity), showing improved thermal stability and resistance to degradation mechanisms; ongoing chip- and device-level reliability studies reported.
Strengthened Intellectual Property Position
Broad portfolio of granted and pending U.S. and international patents covering materials, device architectures, fabrication, integration and packaging; engagement with outside counsel (Michael Best) to expand and reinforce IP strategy for commercialization and licensing.
Strategic Technology Positioning
Company positions its Perkinamine electro-optic polymer as complementary to silicon photonics (enabling higher speed, lower power, smaller footprint and semiconductor-compatible processing), aligning with the industry transition toward silicon photonics (>70% projected share by 2030).
Increased R&D Investment and Operational Execution
R&D investments increased to $3.5M for device performance, reliability validation and integration activities; company reporting disciplined operational progress, ecosystem engagement and steps toward commercial readiness.
Strong Cash Position and Liquidity Update
Ended Q1 2026 with approximately $75M in cash and equivalents; subsequent activity increased cash on hand to approximately $100M as of May 11, 2026 (≈+$25M, +33% vs. quarter end), providing financial flexibility to support roadmap execution.
In-House Manufacturing and Back-End Capability Development
Establishing Perkinamine production line, commissioning equipment and hiring process/production personnel in Denver; currently performing in-house back-end deposition and encapsulation with discussions underway with high-volume partners.